Similar articles

• Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.

  Hocquet D, Muller A, Blanc K, Plésiat P, Talon D, Monnet DL, Bertrand X. Hocquet D, et al. Antimicrob Agents Chemother. 2008 Mar;52(3):1173-5. doi: 10.1128/AAC.01212-07. Epub 2008 Jan 7. Antimicrob Agents Chemother. 2008. PMID: 18180356 Free PMC article.
• Current therapies for pseudomonas aeruginosa.

  Giamarellou H, Kanellakopoulou K. Giamarellou H, et al. Crit Care Clin. 2008 Apr;24(2):261-78, viii. doi: 10.1016/j.ccc.2007.12.004. Crit Care Clin. 2008. PMID: 18361945 Review.
• In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.

  Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. Timurkaynak F, et al. Int J Antimicrob Agents. 2006 Mar;27(3):224-8. doi: 10.1016/j.ijantimicag.2005.10.012. Epub 2006 Feb 7. Int J Antimicrob Agents. 2006. PMID: 16464562
• Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

  Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Kwa AL, et al. Clin Infect Dis. 2005 Sep 1;41(5):754-7. doi: 10.1086/432583. Epub 2005 Jul 20. Clin Infect Dis. 2005. PMID: 16080101
• [Multi-drug resistant Pseudomonas aeruginosa: towards a therapeutic dead end?].

  Barbier F, Wolff M. Barbier F, et al. Med Sci (Paris). 2010 Nov;26(11):960-8. doi: 10.1051/medsci/20102611960. Med Sci (Paris). 2010. PMID: 21106178 Review. French.